Addition of the anti-IL-2 mAb to either elotuzumab or elotuzumab plus lenalidomide-treated co-cultures significantly decreased myeloma cell killing compared with control (Fig. 6a). The gene discussed is IL2; the disease is plasma cell myeloma.